AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

ANB032 was well tolerated across all doses with no safety signals observed; AD trial and all further investment in ANB032 will be discontinued; Anticipate top-line Phase 2b data i ...

Christopher Wray Will Step Down as F.B.I. Director President-elect Trump had already signaled his intention to replace Mr. Wray with a longtime loyalist, Kash Patel. U.S. Colleges Warn Foreign ...

US Bankers Are Cautious Towards Cryptos Despite Upcoming Pro-Crypto Administration ...